Details for Patent: 6,316,471
✉ Email this page to a colleague
Summary for Patent: 6,316,471
Title: | Isoindolines, method of use, and pharmaceutical compositions |
Abstract: | Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline. |
Inventor(s): | Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ) |
Assignee: | Celgene Corporation (Warren, NJ) |
Application Number: | 09/634,061 |
Patent Claim Types: see list of patent claims | Use; Delivery; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 6,316,471
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,316,471
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 229521 | ⤷ Try a Trial | |||
Austria | 275139 | ⤷ Try a Trial | |||
Austria | 401319 | ⤷ Try a Trial | |||
Austria | 460409 | ⤷ Try a Trial | |||
Austria | 500240 | ⤷ Try a Trial | |||
Austria | 530542 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |